{'fraction_non_alphanumeric': 0.02780269058295964, 'fraction_numerical': 0.023318385650224215, 'mean_word_length': 5.065217391304348, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF OFLAXACIN AND SATRINIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC

A simple reverse phase liquid chromatographic method has been developed and subsequently validated for simultaneous determination of Ofloxacin and Satrinidazole in combination. The separation was carried out using a mobile phase consisting of phosphate buffer (0.05M) and Acetonitrile with pH 4.6 adjusted with orthophosphoric acid in the ratio of 70: 30%v/v. The column used was Symmetry C18 (4.6 x 150mm, 5m, Make: Waters) or equivalent with flow rate of 0.8 ml / min using PDA detection at 301 nm. The retention times of Ofloxacin and Satrinidazole were found to be 2.0 and 4.7 min respectively. Results of analysis were validated statistically and by recovery studies. The developed method was validated as per ICH guidelines using the parameters such as accuracy, precision, linearity, LOD, LOQ, ruggedness and robustness. The developed and validated method was successfully used for the quantitative analysis of ofloxacin and Satranidazole in bulk and combined tablet dosage forms.